Parallax Volatility Advisers, L.P. Relmada Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $816,948 - $1.65 Million	-44,642 Reduced 81.05%	10,439 $386,000
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $908,836 - $1.67 Million	55,081 New	55,081 $1.05 Million
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $115,678 - $144,157	-3,670 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$31.52 - $39.28 $115,678 - $144,157	3,670 New	3,670 $129,000
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $378 - $481	-11 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $347 - $549	11 New	11 $0

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.